---
title: "T&K: Wholly-owned subsidiary increases capital and introduces external investors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242529995.md"
description: "T&K announced that its wholly-owned subsidiary Anhui T&K Bioengineering Co., Ltd. has introduced Guangzhou Saifu Biomedical Investment Partnership and Ningbo Haihou Tairen Venture Capital Partnership as external investors through a capital increase. After the capital increase, the registered capital of T&K Bio will rise from 20 million yuan to 39.801 million yuan, and T&K's shareholding ratio will decrease from 100% to 50.25%. The total amount of this capital increase is 55 million yuan"
datetime: "2025-05-30T07:41:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242529995.md)
  - [en](https://longbridge.com/en/news/242529995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242529995.md)
generator: "portal-rs"
---

# T&K: Wholly-owned subsidiary increases capital and introduces external investors

T&K announced that its wholly-owned subsidiary Anhui T&K Bioengineering Co., Ltd. has introduced external investors Guangzhou Sequoia Biomedical Investment Partnership and Ningbo Haihou Tairen Venture Capital Partnership through a capital increase and share expansion. The portion of the capital increase price that exceeds the registered capital will be included in the capital reserve. The registered capital of T&K Bio will increase from 20 million yuan to 39.801 million yuan, and the total shareholding of Anhui T&K in T&K Bio will decrease from 100.00% to 50.25%. T&K Bio has received capital increase payments of 27.5 million yuan each from Sequoia Biomedical and Haihou Tairen, totaling 55 million yuan

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [Ideaship invests in Hemex Health](https://longbridge.com/en/news/297682058.md)
- [05:00 ETNorroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC](https://longbridge.com/en/news/297758164.md)
- [BYD COMPANY  120,000-Tonne Electrolyte Project Nears Commencement of Production](https://longbridge.com/en/news/297747270.md)
- [The biggest "lobster" has been released: OpenClaw 2.0 aims to solve three major problems for agents.](https://longbridge.com/en/news/297578236.md)
- [Shoprite guides FY2027 trading margin to hold at 6% on 53-week basis](https://longbridge.com/en/news/297604039.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**